


HDAC3-IN-2

| | |
|--------------------|---|
| Cat. No.: | HY-156096 |
| CAS No.: | 3033039-28-7 |
| Molecular Formula: | C ₁₆ H ₂₁ N ₅ O ₂ |
| Molecular Weight: | 315.37 |
| Target: | HDAC; Histone Methyltransferase; Caspase; Apoptosis; DNA/RNA Synthesis |
| Pathway: | Cell Cycle/DNA Damage; Epigenetics; Apoptosis |
| Storage: | Please store the product under the recommended conditions in the Certificate of Analysis. |



BIOLOGICAL ACTIVITY

| | |
|---------------------------|---|
| Description | HDAC3-IN-2 (compound 4i) is a pyrazinyl hydrazide-based HDAC3 inhibitor (IC ₅₀ : 14 nM) that efficiently targets triple-negative breast cancer cells. HDAC3-IN-2 is cytotoxic with an IC ₅₀ of 0.55 μM against 4T1 and an IC ₅₀ of 0.74 μM against MDA-MB-231. HDAC3-IN-2 has anti-tumor efficacy in vivo in tumor-bearing mouse models, selectively increasing the acetylation levels of H3K9, H3K27 and H4K12, increasing the contents of apoptosis-related caspase-3, caspase-7 and cytochrome c, and reducing Proliferation-related Bcl-2, CD44, EGFR, and Ki-67 levels ^[1] . |
| IC ₅₀ & Target | IC ₅₀ : 14 nM (HDAC3) ^[1] |

REFERENCES

[1]. Pulya S, et al. Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer. J Med Chem. 2023 Sep 14;66(17):12033-12058...

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA